11th Biological Therapy on Cancer: Challenges of Clinical Drug Development

Due to the exciting developments of molecular biology during the past decade and our increasing understanding of the mechanisms relevant to the genesis of cancer, we are experiencing a transition from disease to target-oriented therapy. This has a strong impact on the development paradigm of cancer therapeutics. Nowhere is this more apparent than in molecular targeted therapy. As with previous meetings, BTOC-11 will focus on the clinical development of a broad spectrum of anti-cancer agents attracting a multi-stakeholder attendance connecting preclinical and clinical scientists, clinicians, healthcare professionals, academia, industry and other stakeholders who are involved in the development of novel anti-cancer agents.